Dario A. Paggiarino Eye Point Pharmaceuticals, Inc. (EYPT) insider trading activity

Dario A. Paggiarino is Chief Medical Officer of EyePoint Pharmaceuticals, Inc.. Currently has a direct ownership of 67,080 shares of EYPT, which is worth approximately $541,335. The most recent transaction as insider was on Mar 30, 2024, when has been sold 25,546 shares (Common Stock) at a price of $20.67 per share, resulting in proceeds of $528,035. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 67.1K

0% 3M change

160.94% 12M change

Total Value Held $541,335

Dario A. Paggiarino Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 30 2024	SELL Payment of exercise price or tax liability	$528,035 $20.67 p/Share	25,546 Reduced 27.58%	67,080 Common Stock
Mar 30 2024	BUY Exercise of conversion of derivative security	-	50,404 Added 35.24%	92,626 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$146,390 $28.8 p/Share	5,083 Reduced 10.75%	42,222 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	10,800 Added 18.59%	47,305 Common Stock
Jan 26 2024	SELL Open market or private sale	$1,259,267 $25.53 p/Share	49,325 Reduced 57.47%	36,505 Common Stock
Jan 26 2024	BUY Exercise of conversion of derivative security	$643,691 $13.05 p/Share	49,325 Added 36.5%	85,830 Common Stock
Jan 25 2024	SELL Open market or private sale	$15,000 $25.0 p/Share	600 Reduced 1.62%	36,505 Common Stock
Jan 25 2024	BUY Exercise of conversion of derivative security	$7,812 $13.02 p/Share	600 Added 1.59%	37,105 Common Stock
Jan 24 2024	SELL Open market or private sale	$281,500 $25.02 p/Share	11,251 Reduced 23.56%	36,505 Common Stock
Jan 24 2024	BUY Exercise of conversion of derivative security	$146,488 $13.02 p/Share	11,251 Added 19.07%	47,756 Common Stock
Jan 23 2024	SELL Open market or private sale	$128,375 $25.0 p/Share	5,135 Reduced 12.33%	36,505 Common Stock
Jan 23 2024	BUY Exercise of conversion of derivative security	$66,857 $13.02 p/Share	5,135 Added 10.98%	41,640 Common Stock
Jan 08 2024	SELL Open market or private sale	$484,151 $21.13 p/Share	22,913 Reduced 38.56%	36,505 Common Stock
Jan 08 2024	BUY Exercise of conversion of derivative security	$74,696 $3.26 p/Share	22,913 Added 27.83%	59,418 Common Stock
Jan 06 2024	SELL Payment of exercise price or tax liability	$91,534 $20.4 p/Share	4,487 Reduced 10.95%	36,505 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	15,285 Added 27.16%	40,992 Common Stock
Dec 13 2023	SELL Open market or private sale	$29,160 $20.0 p/Share	1,458 Reduced 5.37%	25,707 Common Stock
Dec 13 2023	BUY Exercise of conversion of derivative security	$14,769 $10.13 p/Share	1,458 Added 5.09%	27,165 Common Stock
Dec 04 2023	SELL Open market or private sale	$673,750 $22.0 p/Share	30,625 Reduced 54.37%	25,707 Common Stock
Dec 04 2023	BUY Exercise of conversion of derivative security	$310,231 $10.13 p/Share	30,625 Added 35.22%	56,332 Common Stock
Feb 09 2023	SELL Payment of exercise price or tax liability	$15,612 $4.17 p/Share	3,744 Reduced 12.71%	25,707 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	10,800 Added 26.83%	29,451 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$12,875 $9.95 p/Share	1,294 Reduced 6.49%	18,651 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	-	4,105 Added 17.07%	19,945 Common Stock
Feb 09 2022	SELL Payment of exercise price or tax liability	$17,434 $10.13 p/Share	1,721 Reduced 9.8%	15,840 Common Stock

DAP

Dario A. Paggiarino

Chief Medical Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Value

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT

Account